Stem Cells Arabia
12
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells
Role: lead
Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis
Role: lead
Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.
Role: lead
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy
Role: lead
Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy
Role: lead
Transplantation of Autologous Bone Marrow or Leukapheresis-Derived Stem Cells for Treatment of Spinal Cord Injury
Role: lead
Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa
Role: lead
Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells
Role: lead
Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.
Role: lead
Transplantation of Autologous Stem Cells for the Treatment of Type 1 Diabetes Mellitus
Role: lead
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
Role: lead
Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
Role: lead
All 12 trials loaded